Mesoblast's US patents deal lifts shares
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
In a deal with US-based Osiris Therapeutic for an initial $US20 million in cash, along with further future payments, Mesoblast is to gain access to two products in their final stage of clinical trials which already hold approvals for sale in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years.
"These are substantially derisked," Mesoblast chief executive Silviu Itescu said of the two advanced products, an agent for treating some Crohn's disease cases along with a treatment for bone marrow cases resulting from stem cell transplants.
Mesoblast shares closed up 4.7 per cent on Friday at $5.74.
Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells that can help body tissue heal large wounds and repair cartilage and muscle tissue.
Osiris has been producing these stem cells in the US since 1999, and also has a joint venture in Japan.
The acquisition consolidates Mesoblast's position in the regenerative therapies sector, while providing additional growth options, Professor Itescu said.
The acquisition includes approved products in several countries and will "more than double our portfolio of granted patent families encompassing all mesenchymal lineage stem cells", he said. The products will bring forward Mesoblast's projected revenues and provide earlier launch opportunities for products, he said.
A year ago, Osiris regained full control of its prochymal stem cell technology, after terminating a venture with Genzyme potentially worth up to $US1 billion for the US rights alone.
"For $US100 million, Mesoblast is getting two advanced phase-three indications, which is a good deal," Bell Potter analyst Tanushree Jain said.
A key attraction is also the Japan joint venture.
Call 1300 880 160
Start a chat
Schedule a call
